PUBLIC COMPANY
save$VSTMVerastem, Inc.
$VSTMNeedham, MA, USupdated 2mo ago
community read0 votes
pipeline
4
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 32Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- phase2A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- phase3A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- phase2Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
- phase2A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- phase2Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Mar 20, 26grantCalkins Daniel · Chief Financial Officer57 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that